The Massachusetts congressional delegation is seeking answers from the Trump administration after learning of an apparent effort to wind down a medical research hub that opened in Cambridge to much fanfare just over two years ago.
The office under threat, known as the ARPA-H Investor Catalyst Hub, serves the Advanced Research Projects Agency for Health. It’s a federal agency launched during the Biden administration that backs biomedical and health-related research meant to tackle problems that venture capitalists and other private-sector financial backers would usually avoid.
As Congresswoman Lori Trahan told the Globe: “Massachusetts was chosen for the Investor Catalyst Hub, because we have the strongest life science ecosystem in the world. The collaboration between researchers, entrepreneurs and hospitals was exactly what ARPA-H was designed to leverage. Weakening that infrastructure [weakens] the country’s ability to lead in innovation. This decision puts that entire pipeline at risk.”
MassBio was part of the coalition that advocated for bringing the Investor Catalyst Hub to Cambridge in 2023, working alongside Governor Healey’s administration, the Massachusetts Life Sciences Center, Mass General Brigham, and partners across the ecosystem. In its first year, ARPA-H directed nearly $300 million in research funds to companies and nonprofits in Massachusetts.
Read the full story from Jon Chesto in the Boston Globe →
MassBio CEO & President Kendalle Burlin O’Connell had this to say on LinkedIn:
Placing the ARPA-H Investor Catalyst Hub in Cambridge was a strategic decision rooted in proximity to the resources found in one of the strongest life sciences ecosystems in the world. Closing it would be a mistake. Why pull it away from the people, institutions, and companies that give it the best chance at accelerating its mission?
Hosting the hub here was the result of a true Team Massachusetts effort. Over 16 months, Governor Healey and her administration, our congressional delegation, the Massachusetts Life Sciences Center, Mass General Brigham, MassBio, and partners across the ecosystem made the case that Cambridge was the right home for this work.
The Investor Hub has reviewed the groundbreaking science happening here. The result? ARPA-H directed nearly $300 million to Massachusetts companies and nonprofits based on merit-driven reviews in its first year alone. This has helped advance high-risk, high-reward research that often cannot move forward through private capital alone.
Massachusetts is built to translate ambitious science into real-world impact. Cambridge-based Thymmune Therapeutics received up to $37 million for its thymus rejuvenation project, the first industry award through ARPA-H’s Open BAA. Mass General Brigham has also been awarded multiple ARPA-H contracts to deliver hospital-level care to rural communities.
The hub structure makes strategic sense. Congress directed ARPA-H to operate in at least three geographic areas. Placing the Investor Catalyst Hub in the world’s leading life sciences ecosystem, alongside the Customer Experience Hub in Dallas, ensures the agency has access to the right expertise.
Thank you to Congresswoman Lori Trahan and the Massachusetts delegation for doing the digging, demanding answers, and standing up for this key feeder of American innovation. We need Washington to protect what’s working, not dismantle it.